33
Participants
Start Date
December 12, 2018
Primary Completion Date
March 31, 2028
Study Completion Date
December 31, 2028
TAA-T
Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
Brain Tumor Institute, Children's National Medical Center, Washington D.C.
Collaborators (1)
Children's National Research Institute
OTHER
Catherine Bollard
OTHER